Article Text

Download PDFPDF

TP004/#1496  Sentinel lymph node biopsy versus pelvic lymphadenectomy in early- stage cervical cancer: a multi-center randomized trial
  1. Hua Tu1,
  2. Yanfang Li1,
  3. Yanling Feng1,
  4. Xiaojun Chen2,
  5. Min Zheng1,
  6. Chunyan Wang3,
  7. Weidong Zhao4,
  8. Weiwei Shan2,
  9. Ping Zhang5,
  10. Weiguo Lv6,
  11. Jing Xiao7,
  12. Weiwei Feng8,
  13. Beihua Kong9,
  14. Xipeng Wang10 and
  15. Jihong Liu1
  1. 1Sun Yat-sen University Cancer Center, Department of Gynecologic Oncology, Guangzhou, China
  2. 2Obstetrics and Gynecology Hospital of Fudan University, Gynecology, Shanghai, China
  3. 3Cancer Hospital of ChinaMedical University, Liaoning Cancer Hospital and Institute, Department of Gynecology, Shenyang, China
  4. 4The First Affiliated Hospital of USTC, University of Science and Technology of China, Gynecologic Oncology, Hefei, China
  5. 5Zhejiang Cancer Hospital, Gynecologic Oncology, Hang Zhou, China
  6. 6Zhejiang University School of Medicine Women’s Hospital, Gynecologic Oncology Department, HangZhou, China
  7. 7Guangdong Province Traditional Chinese Medical Hospital, Gynecologic Oncology, Guang Zhou, China
  8. 8Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Department of Gynecology and Obstetrics, Shanghai, China
  9. 9Qilu hospital of Shandong University, Obstetrics and Gynecology, Jinan, Shandong province, China
  10. 10XinHua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Department of Gynecology and Obstetrics, Shanghai, China


Introduction Sentinel lymph node (SLN) biopsy has long been considered as an alternative for pelvic lymphadenectomy in cervical cancer. However, the optimal strategy for applying SLN biopsy in cervical cancer remains lacking.

Methods We are performing a multicenter, randomized controlled trial to compare the two approaches for lymph node dissection in cervix cancer (PHENIX trial, number, NCT02642471). We enroll patients with FIGO 2018 stage IA1 (lymphovascular space involvement), IA2, IB1, IB2 and IIA1 cervical squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma. SLN biopsy were performed at the start of surgery. The SLNs were submitted for frozen section examination and patients were triaged into the PHENIX-I (SLN-negative) or PHENIX-II (SLN-positive) cohort. In each cohort, patients were randomized in a 1:1 ratio into the experimental (SLN biopsy alone) or reference (pelvic lymphadenectomy) arm. This trial was designed with non-inferiority hypothesis and the primary endpoint is disease-free survival. Estimated sample sizes of 830 and 250 are required to fulfill the study objectives of PHENIX-I and II, respectively.

Current Trial Status Up to June 2023, 826 and 67 patients enrolled PHENIX-I and PHENIX-II cohort, respectively. Twenty-five patients were excluded due to inappropriate postoperative pathology. Among the current data, the bilateral detecting rate of SLN was 82.4%. The frozen section examination was found false-negative in 7 patients and false-positive in 3. Adjuvant therapies were administered in 47.9% patients with pathological risks. The median follow-up time reached 30 months. Neither of the cohorts showed difference in disease-free survival between the arms. The final presentation of results is expected in 2026.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.